Clinical

Videos

Moreau discussed conclusions drawn from part 2 of the CASSIOPEIA trial and the need for further follow-up with bortezomib, thalidomide and dexamethasone plus maintenance daratumumab in newly diagnosed multiple myeloma.

Philippe Moreau, MD, on Conclusions With VTd Plus Daratumumab in Newly Diagnosed Myeloma at ASCO 2021

At EHA 2021, Shaji Kumar, MD, reviews the toxicity profile of daratumumab plus lenalidomide and dexamethasone for patients with transplant-ineligible multiple myeloma in the first-line setting.

Shaji Kumar, MD, Details Toxicities With Daratumumab Plus Lenalidomide/Dexamethasone in Frontline MM

Articles

The FDA approved the combination of daratumumab and hyaluronidase-fihj plus pomalidomide/dexamethasone as therapy for certain patients with pretreated multiple myeloma. 

Subcutaneous Daratumumab Indication Expanded to Include Pomalidomide/Dexamethasone Combo for Relapsed Myeloma

At ASCO 2021, Shaji Kumar, MD, talked about the impact of adding daratumumab maintenance to therapy for patients with newly diagnosed multiple myeloma in the CASSIOPEIA trial. 


Shaji Kumar, MD, on Daratumumab Maintenance Following Transplant for Myeloma in CASSIOPEIA 

During a discussion at ASCO 2021, Mounzer Agha, MD, talked about mitigation strategies used by the investigators from the CARTITUDE-2 trial to prevent cognitive and neuro-movement disorders commonly associated with CAR T-cell therapy.

Mounzer Agha, MD, Reviews the Safety Profile of Ciltacabtagene Autoleucel in Multiple Myeloma

The FDA has requested a partial clinical hold on all trials featuring melflufen following the updated results of the phase 3 OCEAN study in relapsed/refractory multiple myeloma.

FDA Has Requested a Partial Clinical Hold on All Trials With Melflufen in Following Study in R/R Myeloma

Moreau detailed the patient characteristics of those enrolled on the CASSIOPEIA trial, which investigating bortezomib, thalidomide and dexamethasone plus daratumumab in patients with newly diagnosed multiple myeloma.



Philippe Moreau, MD, on Results With Daratumumab Plus VTd in Newly Diagnosed Myeloma at ASCO 2021

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of a daratumumab combination in patients with multiple myeloma.

Shaji Kumar, MD, Reviews PFS With Daratumumab-Containing Therapy in Frontline Myeloma 

Agha emphasized that the annual conference allows investigators to set the foundation for what’s to come in the treatment of multiple myeloma and other hematologic malignancies.

Mounzer E. Agha, MD, Discussed the Value of ASCO Annual Meeting for Multiple Myeloma

Final overall survival results from TOURMALINE-MM1 failed to show statistical significance of an ixazomib combination for relapsed/refractory multiple myeloma overall. 

Multiple Myeloma | Topics